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IDENTIFICATION OF BRAIN LESIONS IN 
NEUROPSYCHIATRIC SYSTEMIC LUPUS 
ERYTHEMATOSUS BY 
MAGNETIC RESONANCE SCANNING 
W. JOSEPH McCUNE, ANNE MAcGUIRE, ALEX AISEN, and STEPHEN GEBARSKI 
Cranial magnetic resonance imaging in 28 sys- 
temic lupus erythematosus patients who had experi- 
enced 30 acute neuropsychiatric events showed focal 
brain lesions in 16 of 30 events (53%) and low brain 
volume (atrophy) in 20 of 30 events (67%). Definite focal 
lesions were significantly more frequent in patients with 
clinically localized neurologic deficits (8 of 8, loo%), or 
seizures (5 of 6, 83%) than in patients without such 
localizing signs (3 of 16, 19%). Many of these lesions 
were occult on intravenous contrast-enhanced x-ray 
computed tomography. In 2 patients, lesions in gray 
matter resolved within 2 or 3 weeks, in association with 
clinical improvement. Magnetic resonance imaging is an 
important technique for detecting the extent of brain 
injury in cerebral lupus. 
Significant neuropsychiatric events occur in as 
many as 70% of patients with systemic lupus erythema- 
tosus (SLE) (1,2). Despite the frequent occurrence of 
neuropsychiatric lupus (NPSLE), our understanding of 
these events has recently been said to be comparable 
with our understanding of lupus nephritis 30 years ago 
(1). A useful classification scheme is needed (3,4). In  2 
large studies, pathologic findings at autopsy correlated 
poorly with clinical events, and showed vasculitic le- 
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sions typical of extracranial SLE in only a fraction of 
patients (5,6). These studies were complicated by the 
failure to distinguish between “primary” neuropsy- 
chiatric events that presumably result from the direct 
effect of active SLE on the nervous system and “sec- 
ondary” events that result indirectly from SLE-induced 
dysfunction of organs outside the nervous system (e.g., 
uremia, hypertension), or from the side effects of drug 
therapy for SLE (4). 
Before the introduction of magnetic resonance 
imaging (MRI), there was no satisfactory method of 
consistently identifying localized cerebral lesions in 
NPSLE. The few focal lesions detected by x-ray 
computed tomography (CT) have correlated well with 
clinical findings, but such abnormalities were often not 
demonstrated in patients with clinical evidence of 
recent strokes or seizures (7-9). Other imaging meth- 
ods used to identify brain lesions in NPSLE have 
limitations in sensitivity (angiography), specificity (oxy- 
gen 15 positron emission tomography) (lo), or in both 
(radionuclide brain scanning) ( 1  1-13). 
MRI offers several theoretical advantages over 
CT when applied to brain imaging; notably, better 
intrinsic resolution of various normal and pathologic 
tissues without the need for intravenous contrast ma- 
terial, lack of beam hardening and scatter artifacts 
from surrounding bone, and availability of images in 
multiple orthogonal planes without manipulation of the 
patient (14). Using current technology, the improved 
sensitivity of MRI compared with that of CT in the 
central nervous system (CNS) has been demonstrated 
in the majority of patients with noncalcified non- 
hemorrhagic brain lesions >3 mm in diameter (15-17). 
Previous studies that were limited to the description of 
only those patients who had abnormal results on MRI 
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have suggested improved sensitivity compared with 
CT in NPSLE (18,19). 
We obtained cranial MRI scans in 28 patients 
with 30 recent neuropsychiatric events that were as- 
sociated with SLE; I patient was studied on 3 different 
occasions. Our findings suggest that MRI detects more 
local abnormalities in specific clinical subsets of pa- 
tients with NPSLE than does  CT. Because MRI was  
more sensitive than CT only in the presence of specific 
clinical findings, we conclude that the additional ab- 
normalities detected were real and not artifacts. 
PATIENTS AND METHODS 
Patients. Patients were included in this study only if 
they fulfilled all of the following criteria: 1 )  Admission to the 
University of Michigan Hospital and/or had received outpa- 
tient care in the rheumatology clinic. 2) Documentation of 4 
American Rheumatism Association ( A M )  criteria for SLE 
(20). The ARA criterion of neuropsychiatric disease was 
considered to be fulfilled only if a seizure or psychosis was 
documented in the absence of a secondary cause as defined 
below. 3) A significant change in neuropsychiatric status 
potentially attributable to SLE, its complications, or treat- 
ment, within the preceding 4 weeks (acute disease). 4) 
Performance of a formal neurologic examination. 
After permission was obtained from the patient’s 
attending physician, all patients with acute NPSLE known 
to the investigators who satisfied the above criteria over a 
16-month period were offered the opportunity to have MRI 
scanning performed. Patients for whom MRI scanning was 
contraindicated (pregnancy, metal clips near great vessels, 
or an acute medical problem that rendered them too unstable 
to undergo a scan) were excluded. Written consent was 
obtained prior to MRI. Further studies, including CT, elec- 
troencephalogram, and cerebrospinal fluid (CSF) analysis, 
were carried out at the discretion of the attending physicians 
and were not specifically performed as part of the protocol. 
Records of all patients from the time of diagnosis of 
SLE were reviewed in their entirety. Clinical, laboratory, 
and imaging data were tabulated in chart form by an inves- 
tigator (AM) who was unaware of the results of MRI scan 
interpretations. Particular attention was paid to previous 
neurologic events, evidence of vasculitis. vasoocclusive 
disease, or coagulopathies. The following data were specif- 
ically sought: I )  the age at diagnosis (4 ARA criteria for SLE 
or, in the absence of detailed records, the age at onset of 
obvious multisystem disease that was typical of SLE); 2) the 
presence of vasculitis, either proven by biopsy, or obvious 
cutaneous infarction or purpura; 3) thrombotic episodes, 
including lower extremity thrombophlebitis, pulmonary em- 
bolism, angiographic and/or biopsy-proven thrombosis in 
other organs; 4) prolongation of the partial thromboplastin 
time (PTT; upper limit of normal 28 seconds) at any time 
during the clinical course in the absence of anticoagulation 
therapy, disseminated intravascular coagulation, or an inher- 
ited coagulopathy. In addition, the prednisone “index” was 
said to be the integral, over time, of all doses of prednisone 
documented in the chart, assuming that the patient took the 
recorded dose constantly until a change was recorded. 
Laboratory values, including CSF analysis, complement 
CH50 determinations using the modified method described 
by Kent and Fife (21), and serum antibodies to double- 
stranded DNA by the Farr or Crithidia assays, were re- 
corded if determined within 4 weeks of the event on the date 
closest to the event studied. All previous neurologic events 
were recorded in detail. 
Neuropsychiatric events were classified according to 
the following criteria (based on clinical findings in the 4 
weeks preceding MRI). Group I :  Group 1 included all 
patients with a new localizing physical finding on neurologic 
examination that was attributable to a brain lesion. Group 2: 
Group 2 was composed of all patients with either witnessed 
or self-reported seizures that were corroborated by EEG 
findings, who did not qualify for inclusion in group 1.  Group 
3: Group 3 included all other patients with significant neu- 
ropsychiatric events who did not meet criteria for inclusion 
in group 1 or group 2. Included were patients with progres- 
sive organic brain syndrome$. psychoses, headaches, or 
meningeal signs that prompted hospital admission. self- 
reported localizing neurologic deficits (visual or motor) not 
accompanied by corresponding findings on neurologic exam- 
ination, drug toxicity, and transverse myelitis. 
Neurologic events were further classified as primary 
(presumably resulting from active SLE affecting the brain) or 
secondary (possibly resulting indirectly from SLE activity 
that is primarily affecting organs outside of the CNS) if 1 or 
more of the following critiera were present: uremia (blood 
urea nitrogen > 100 or dialysis), hypertension (diastolic 
blood pressure > I10 mm Hg), hypoxia (decrease in Po, to 
<60), culture-proven systemic or CNS infection, serious 
electrolyte imbalances, probable side effects of drugs, or 
thrombocytopenia (platelet count <50,000/mm3) accompa- 
nied by CNS hemorrhage (4). 
MRI. MRI was performed utilizing a Diasonics MT/S 
system employing a super-conducting 0.5 tesla (T) magnet 
operating at 0.35T. All images were obtained with multislice. 
spin-echo technique imaging hydrogen nuclei; 7 mm-thick 
sections at 10-mm intervals were obtained, with 1.7 X 
1.7-mm resolution. Axial imaging sequences with a pulse 
repetition time (TR) of 2,000 ms and echo time (TE) of 28 and 
56 ms were performed on all patients. This sequence empha- 
sizes spin-spin transverse relaxation time (T,) abnormali- 
ties. Such emphasis is commonly referred to as T, weighting. 
This sequence delivers 20 pairs of axial images in approxi- 
mately 17 minutes. Initially, patients also received a second 
axial sequence with balanced (TR 1,000 ms, TE 28 and 56 
ms) technique, that is, without dominant weighting for spin 
lattice relaxation time (TI)  or for T,. This sequence delivers 
10 axial images in approximately 5 minutes. This balanced 
technique did not prove useful and was replaced by a 
TI-weighted (TR 500 ms, TE 28 ms) axial sequence which 
delivers 10 axial image pairs in approximately 8 minutes. 
Questionable abnormalities seen using the T,-weighted se- 
quence would result in the patient receiving a corroborative 
coronal sequence with relative T2 weighting (TK 1,500 ms, 
TE 28 and 56 ms) delivering 15 coronal sections in approx- 
imately 13 minutes. 
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Table 1. Acute neuropsychiatric events in 28 patients with 
systemic lupus erythematosus 
Classification No. 
Group I (focal events) 
Group 2 (seizures) 
Simple 
Complex 
Organic brain syndromes 
Psychosis 
Headaches or meningeal signs 
Visual or motor symptoms (normal results on 
Plaquenil toxicity 
Transverse myelitis 














CT. Computed tomography scans obtained early in 
the study were by an EM1 1005 dedicated head scanner 
updated to 1010 performance. CT scans obtained later were 
by General Electric 8800 or 9800 units. Intravenous contrast 
enhancement was used in most patients, and was omitted in 
patients only because of a history of contrast sensitivity, 
renal insufficiency, and/or emergency indications for CT, 
generally, clinical suspicion of intracranial hemorrhage, re- 
quiring non-contrast-enhanced CT. Nineteen patients un- 
derwent CT. 
MRIlCT interpretation. All MRI scans were inter- 
preted at the time of acquisition by 2 investigators (AA, 
WJM), and additional sequences were obtained if needed, 
using the method described above. At the conclusion of this 
study, all MRI sequences, both T,- and T,-weighted, were 
interpreted in a blinded manner ( 5  normal controls inter- 
mixed, the interpreter unaware of the patient’s medical 
diagnosis or previous scan interpretations) by a neuroradio- 
logist (SG). Definite circumscribed abnormalities were con- 
sidered to be present if they were positively identified in any 
pulse sequence. The only information provided at the time of 
the neuroradiologist’s interpretation was the age and sex of 
the patient. CT was interpreted by the neuroradiologist 
without identification of the corresponding MRI scan, again 
in the blinded manner described above. 
MRI and CT interpretations were recorded sepa- 
rately, on a standardized form during blinded reading. Cir- 
cumscribed parenchymal lesions were classified as definite 
or equivocal, and their size, location (peripheral, junctional, 
or periventricular), and the dominant type of brain tissue 
A B 
Figure 1. A, Computed tomogram of a 52-year-old woman with lupus and partial complex seizure activity, showing no abnormalities. B, 
Cranial magnetic resonance scan obtained at the same time and at the same level, showing new appearance of multiple white matter lesions 
(arrows) which were absent on a magnetic resonance scan obtained I year previously. 
162 McCUNE ET AL 
Figure 2. Magnetic resonance scan of a 36-year-old woman with 
multiple strokes and a seizure disorder. There are multiple periep- 
endymal white matter lesions (black arrows), a new junctional lesion 
that predominantly involves gray matter (white arrow), and deep 
white matter lesions (arrowheads). 
affected (white matter, gray matter, or both) were identified. 
The degree of low brain volume for age, or atrophy, was 
assessed in 4 areas: supratentorial and infratentorial super- 
ficial brain tissue, and supratentorial and infratentorial deep 
brain tissue. In each location, the degree of atrophy was 
subjectively ranked from 0 (normal) to 3 (very severe). For 
each patient, the atrophy score was determined as the sum of 
the numerical values assigned to each of the 4 regions. Thus, 
a normal atrophy score was 0, and the maximum possible 
abnormality score was 12. 
Statistical methods. Results were analyzed by Fish- 
er's exact test, with Yates' correction where deemed appro- 
priate. Grouped numerical results were compared by logistic 
regression. For comparison of numerical results in the 
patient with multiple events, the second event was arbi- 
trarily selected. 
RESULTS 
All of the normal subjects ( 5  individuals) had 
normal scan results. Thirty acute events were studied 
in 28 patients (8 group 1 events, 6 group 2 events, 16 
group 3 events) (Table 1). Twenty-three events were 
primary and 7 were secondary. Only 3 of the events 
were accompanied by additional neurologic findings 
which, if present in isolation, would have resulted in 
assignment to a different category of neurologic event 
(e.g., group 2, rather than 1 or 3); 27 events were in 1 
specific category, and did not have elements of an 
additional category as a confounding feature. Focal 
events occurred more than 1 month prior to entry into 
the study in one group 2 patient and one group 3 
patient. Characteristic images obtained from study 
patients are shown in Figures 1 and 2. 
Relationship of previous neuropsychiatric events 
to group assignment. There was a tendency for previ- 
ous neuropsychiatric events to be classified into the 
same clinical group as the current neuropsychiatric 
events studied in individual patients. Thus, in the events 
studied, 17 patients had previous recorded events which 
would have been assigned to the same group, whereas 
prior events which would have been classified differently 
occurred in only 10 patients. 
MRI identification of circumscribed brain lesions 
in blinded readings. Among the 30 studies obtained, it 
was possible to  definitely judge focal lesions to be 
present or absent in 28 (Table 2). Two studies (one from 
a group 2 patient and one from a group 3 patient) 
Table 2. 
patients 
Identification of circumscribed brain lesions by magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus 
- 
All events Primary events 
No. of Lesions Lesions Lesions No. of Lesions Lesions Lesions 
Subjects events* present equivocal absent eventst present equivocal absent 
~ 
Group I 8 8 0 0 6 6 0 0 
Group 2 6 5 I 0 4 3 I 0 
Group 3 16 3 I 12 13 2 I 10 
Control subjects 5 - - - - - - - 
* Comparing number of patients with positive results versus number with negative results, P < 0.01, group 1 versus group 3 and group 2 versus 
group 3. 
t Comparing number of patients with positive results versus number with negative results. P < 0.05, group I versus group 3. 
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showed equivocal abnormalities, possibly because of 
technical limitations of MRI, and are excluded from this 
part of the analysis. Eight of 8 group 1 scans (100%) and 
5 of 5 group 2 scans (100%) had positive results, 
compared with 3 of 15 group 3 scans (20%) (group 1 
versus group 3 P < 0.01; group 2 versus group 3 P < 
0.01) When only a single event was analyzed for each 
patient (the chronologically latest event was arbitrarily 
selected), these correlations again had a slightly greater 
level of significance. When only patients with neuropsy- 
chiatric events classified as primary (that is, without 
known possible etiologies for CNS disease other than 
SLE) were analyzed, there was again a significant 
difference between group 1 and group 3 patients. 
The majority of the lesions were quite obvious to 
all observers. All lesions previously noted by unblinded 
observers were recognized by the blinded observer, 
who noted 1 additional lesion in group 1, 1 in group 2, 
and 2 in group 3. There were 6 lesions confined to gray 
matter, 6 lesions confined to white matter, and 4 lesions 
that overlapped. In group 1 ,6  of 8 scans showed lesions 
in the appropriate hemisphere and in an anatomic 
location that corresponded to clinical findings. We were 
unable to differentiate abnormalities in patients in group 
2 (seizures) from those in group 1 (focal signs) on the 
basis of the location of lesions. 
Identification of brain atrophy by MRI scanning. 
Minor degrees of atrophy affecting the superficial brain 
structures above and below the tentorium were com- 
mon, but severe atrophy or atrophy of deep structures 
was uncommon. 
Atrophy was identified on 20 scans (67%), with 
a mean score of 1.5 (range 0-12) in affected patients. 
Superficial atrophy was noted on 20 scans; atrophy of 
deep structures was noted on 2 scans (P < 0.01). 
Atrophy was noted in 6 of 8 group 1 scans (75%), 5 of 
6 group 2 scans (83%), and 9 of 16 group 3 scans (56%). 
Atrophy and/or a focal abnormality was present in 23 
scans. The atrophy score was low in all patients, and 
reflected, in part, the localization of most findings to 
the supratentorial superficial structures (range of pos- 
itive scores 1-3) and absence of findings in the 3 other 
areas evaluated. In all instances, patients with atrophy 
had diffuse involvement of the region evaluated, in- 
cluding areas not containing focal lesions. 
Relationship of clinical and laboratory para- 
meters to MRI scan interpretations. The most signifi- 
cant parameter associated with MRI scan findings by 
multivariate analysis was age. Patients with focal 
lesions were significantly older than unaffected pa- 
tients, and patients with atrophy were younger than 
those without atrophy, as shown in Table 3. Review of 
the findings depicted in Table 3 suggests a number of 
other possible associations which did not achieve 
statistical significance, including association between 
vascular thrombosis and focal lesions, and association 
of vascular thrombosis, prolongation of the PTT, and a 
high degree of prednisone intake with cerebral atro- 
phy. There was no relationship of imaging findings to 
levels of anti-DNA antibodies, CH50, or CSF protein, 
glucose, or cell count. 
CT. CT scans were obtained for 19 patients. 
Focal lesions were identified in 5 of 19 CT scans (26%), 
compared with 12 of 19 MRI scans (63%). CT and MRI 
were obtained in close temporal relationship, with an 
average time interval of 40 hours. One patient had 
equivocal abnormalities on both MRI and CT. There 
was substantial consistency between MRI and CT 
results in the identification of focal lesions in group 3 
patients, since results of almost all scans were nega- 
tive. In contrast, focal lesions were identified by CT in 
only 2 of 6 patients in group 1 and 2 of 4 patients in 
group 2, compared with 10 of 10 positive correspond- 
ing MRI scans in groups 1 and 2. Thus, in patients at 
greatest risk for focal lesions (group 1 and group 2), 4 
of 10 CT scans, compared with 10 of 10 MRI scans, 
gave positive results ( P  < 0.05). All lesions identified 
on CT were also identified on MRI. As shown in Table 
4, lesions which were identified by MRI were also seen 
by CT in 1 of 5 scans with isolated white matter 
Table 3. Correlation of clinical and laboratory parameters with 
magnetic resonance imaging findings in 28 patients with 
neuropsychiatric systemic lupus erythematosus* 
Focal lesions Atrophy 
Present Absent Present Absent 
Median age 
History of vascular 
History of vasculitis 
Prednisone index >25 gm 
(lifetime intake) 
History of prolonged FTT 
(normal 13-28) 
Cerebrospinal fluid 
White cells >5/mm3 
Protein >40 mg% 
thrombosis 
Serum CH50 (100 (normal 
Serum DNA binding >25% 





























* Except for the age parameter, numbers are the no. found/no. of 
patients tested. PTT = partial thromboplastin time. 
t P < 0.05 versus absent. 
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involvement (20%), and 1 of 4 scans with isolated gray 
matter involvement (25%), compared with 3 of 4 scans 
with involvement of both white matter and gray matter 
(75%). Lesions that involved both white and gray 
matter tended to be larger than those that did not. 
In paired CT and MRI scans, blinded subjective 
evaluation of atrophy (performed on separate occa- 
sions without patient identification) showed an atro- 
phy score 2 1 in 6 of 17 CT scans compared with 1 1  of 
17 MRI scans (P  not significant). As in MRI evalua- 
tions, the degree of atrophy seen by CT was mild. 
Transient focal lesions. In 2 patients, 1 with 
aphasia and hemiparesis and 1 with a seizure which 
occurred while the patient was hypertensive and ure- 
mic, MRI demonstrated unequivocal single focal le- 
sions which, on repeat MRI scans obtained within 2-3 
weeks, appeared to have resolved. Both lesions were 
located primarily in gray matter and were not demon- 
strated, even in retrospect, by emergency non-con- 
trast-enhanced CT. In both patients, clinical symp- 
toms resolved in parallel with resolution of abnor- 
malities on the scans. 
DISCUSSION 
In 28 patients with active neuropsychiatric 
SLE, MRI detected focal lesions in 16 of 30 scans and 
atrophy in 20 of 30 scans, with some abnormality seen 
on 23 of 30 scans. In this series, the presence or 
absence of circumscribed brain lesions correlated well 
with clinical evidence of either focal neurologic defi- 
cits or seizures, and the correlation was better than 
that obtained using CT. Although the classification 
scheme of clinical events was designed so that patients 
with multiple manifestations were more frequently 
assigned to groups 1 and 2, most patients did not have 
Table 4. Characteristics of focal lesions identified in patients 
who had undergone both magnetic resonance imaging (MRI) and 
computed tomography (CT) scans 
No. (%) of No. (%) of 
patients with patients with 
lesions lesions 
No. of detected by detected by 
Location of lesion patients MRI CT 
Isolated to white or 
gray matter 9 9 (100) 2 (22) 
White matter only 5 5 (100) 1 (20) 
Overlapping lesions 4 4 (100) 3 (75) 
Total 13 13 (100) 5 (38) 
Gray matter only 4 4 (loo) l(25) 
overlapping acute symptoms, as shown in Table 3, and 
it appears unlikely that bias toward including patients 
with more severe disease in these groups was solely 
reponsible for the marked increase in the occurrence 
of focal lesions in groups 1 and 2 compared with group 
3 .  Our data suggest that the presence of focal abnor- 
malities seen on MRI is characteristic of the occur- 
rence of seizures and strokes in SLE patients, even 
when the accompanying CT result is negative. An 
underlying pathophysiologic process which can pro- 
duce localized brain abnormalities, with or without 
additional diffuse brain injury, should be sought. 
Sequential observation of 2 reversible lesions, 
each of which was not detectable by CT, showed 
direct correlation between resolution of abnormalities 
seen on MRI and clinical improvement. This correla- 
tion suggests that either the abnormalities detected by 
MRI may improve in many patients because of partial 
or complete reversal of parenchymal injury, accompa- 
nied by clinical improvement, or that the lesion does 
not heal, but becomes undetectable by current MRI 
techniques concomitantly with recruitment of alter- 
nate neuronal pathways to restore clinical function. 
The excellent correlation of focal lesions seen on MRI 
with acute events (limited to only the 4 weeks preced- 
ing MRI) without consideration of prior events may be 
related, in part, to resolution of focal lesions which 
might have been transiently present in those patients 
with group 3 events who had previous events classified 
as group 1 or group 2. 
In our series, lesions confined either to gray 
matter or to white matter tended to be smaller than 
lesions involving both gray and white matter. This may 
explain why overlapping lesions were most reliably 
detected by CT. Alternatively, isolated gray or white 
matter lesions might have different imaging character- 
istics due to a different type of tissue injury. 
Cerebral atrophy was a frequent MRI finding, 
and was usually confirmed by CT. Atrophy tended to 
be superficial rather than deep, and ventricular en- 
largement was distinctly uncommon. The majority of 
patients had findings confined to the superficial, supra- 
tentorial region. The mean score of 1.5 (on a scale of 
0-3) is representative of mild-to-moderate abnormality 
in this region, with only a minimal contribution from 
the 3 other areas scored. It was the subjective judg- 
ment of our blinded observer (SG), as well as the 2 
other investigators (AA, WJM) that the findings, in 
general, were mild, although definite and easily distin- 
guished from those on the scans of the normal con- 
trols. Although there was a tendency for atrophy to 
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occur more frequently in patients in group 1 and group 
2, as well as in patients who also had focal lesions seen 
on MRI, these associations reached only marginal 
statistical significance. Atrophy has previously been 
thought, by some investigators (22-25), to be related to 
steroid therapy, and there was a tendency for it to be 
associated with higher steroid doses in this study. 
When both techniques were used, more lesions 
were identified by MRI than by CT. The comparison 
may not reflect findings detected using optimal CT 
techniques, because practical considerations pre- 
cluded obtaining studies with and without contrast in 
all patients. However, because CT was ordered by the 
attending physician only when it was thought to be 
clinically indicated (and was not routinely performed 
as part of the protocol), it is possible that patients 
whose physicians considered them to be more se- 
verely ill were more likely to undergo CT. Therefore, 
they might have been more likely to have positive 
findings than those patients for whom CT was not 
ordered. When emergency studies were performed, 
CT was always obtained first and MRI was obtained 
only when the patient was stable, usually 12-48 hours 
later. It is possible that if CT scans had been obtained 
longer after the acute event, additional findings might 
have been noted. It is also possible that findings on 
some MRI scans might have been negative if they had 
been obtained earlier. 
Although assessments of the specificity of our 
findings for lupus-mediated CNS damage will require 
additional control subjects without neuropsychiatric 
lupus as well as steroid-treated control subjects with- 
out lupus, the very low incidence of focal lesions in 
group 3 patients, who were frequently treated with 
steroids, suggests that focal lesions would be at least 
equally uncommon in a control population. There are 
no published data regarding MRI of steroid-treated 
patients who do not have central nervous system 
disease. Interpretation of findings of cerebral atrophy, 
which correlated positively with estimated prednisone 
dosage, will be aided by such studies. 
Our findings suggest that the presence or ab- 
sence of focal lesions in lupus patients with acute 
neuropsychiatric events is currently best determined 
by MRI. Presently, abnormal findings would appear to 
be most useful in patient management when clinical 
suspicion of a lesion in a specific location is confirmed, 
since the significance of asymptomatic lesions and the 
incidence of focal abnormalities in lupus patients who 
do not have clinical evidence of neurologic dysfunc- 
tion is currently unknown. 
Although MRI is quite sensitive, its specificity 
is limited. In most patients, it would not be possible to 
suggest a diagnosis of CNS lupus from radiographic 
findings alone, in the absence of clinical history. For 
example, it was often not possible to differentiate the 
focal white matter lesions seen in several of our 
patients from those found in patients with ischemic 
disease or multiple sclerosis. In a small number of 
patients, the MRI findings alone can suggest a diagno- 
sis of vasculitis: for example, a young patient with 
multiple small gray and white matter lesions in multi- 
ple artery territories. 
As noted in Patients and Methods, we used 
both TI- and T,-weighted images for most patients. We 
believe this adequately covered the gamut of CNS 
pathologic findings. Other pulse sequences, such as 
inversion recovery, are unlikely to provide additional 
information. Scans in additional planes could have 
been performed (e.g., coronal or sagittal) for corrob- 
oration of equivocal findings, but this was generally 
not possible because of the time limitations. 
Improved detection of the anatomic location of 
brain injury may assist in classifying NPSLE patients 
into appropriate subgroups for further study. MRI 
appears to provide a superior means of documenting, 
over time, the presence and course of cerebral injury 
in lupus. This technique may prove particularly valu- 
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